Spannella Francesco, Giulietti Federico, Balietti Paolo, Borioni Elisabetta, Lombardi Francesca E, Ricci Maddalena, Cocci Guido, Landi Laura, Sarzani Riccardo
aInternal Medicine and Geriatrics, 'Hypertension Excellence Centre' of the European Society of Hypertension, IRCCS-INRCA, 'U. Sestilli' bDepartment of Clinical and Molecular Sciences, University 'Politecnica delle Marche', Ancona, Italy.
J Hypertens. 2017 Nov;35(11):2315-2322. doi: 10.1097/HJH.0000000000001438.
Angiotensin-converting enzyme inhibitors (ACE-I) and AT1 blockers (ARB) are commonly used antihypertensive drugs, but several factors may affect their effectiveness. We evaluated the associations between ambulatory blood pressure (BP) monitoring (ABPM) parameters and plasma renin activity (PRA)-to-plasma aldosterone concentration (PAC) ratio (RAR) to test renin-angiotensin-aldosterone system inhibition in essential hypertensive patients treated with ACE-I or ARB for at least 12 months.
We evaluated 194 consecutive patients referred to our Hypertension Centre. ABPM, PRA and PAC tests were performed without any changes in drug therapy. RAR, PRA and PAC tertiles were considered for the analyses.
Mean age: 57.4 ± 12.0 years; male prevalence: 63.9%. No differences between RAR tertiles regarding the use of ACE-I or ARB (P = 0.385), as well as the other antihypertensive drug classes, were found. A reduction of all ABPM values considered (24-h BP, daytime BP and night-time BP and 24-h pulse pressure (PP), daytime PP and night-time PP) and a better BP control were observed at increasing RAR tertiles, with an odds ratio = 0.12 to be not controlled during night-time period for patients in the third tertile compared with patients in the first tertile (P < 0.001). This association remained significant even after adjusting for 24-h BP control. All the associations were also confirmed for PRA tertiles, but not for PAC tertiles.
Higher RAR values indicate effective renin-angiotensin-aldosterone system inhibition and lower night-time and pulse pressures in real-life clinical practice. It could be a useful biomarker in the management of essential hypertensive patients treated with ACE-I or ARB.
血管紧张素转换酶抑制剂(ACE-I)和AT1受体阻滞剂(ARB)是常用的降压药物,但有几个因素可能会影响其疗效。我们评估了动态血压监测(ABPM)参数与血浆肾素活性(PRA)与血浆醛固酮浓度(PAC)之比(RAR)之间的关联,以检测接受ACE-I或ARB治疗至少12个月的原发性高血压患者的肾素-血管紧张素-醛固酮系统抑制情况。
我们评估了194例连续转诊至我们高血压中心的患者。在药物治疗无任何改变的情况下进行ABPM、PRA和PAC检测。分析时考虑了RAR、PRA和PAC三分位数。
平均年龄:57.4±12.0岁;男性患病率:63.9%。在ACE-I或ARB的使用方面,RAR三分位数之间没有差异(P=0.385),其他降压药物类别之间也没有差异。随着RAR三分位数的增加,观察到所有考虑的ABPM值(24小时血压、日间血压、夜间血压以及24小时脉压(PP)、日间PP和夜间PP)均降低,且血压控制更好,与第一三分位数的患者相比,第三三分位数的患者夜间未得到控制的比值比为0.12(P<0.001)。即使在调整24小时血压控制后,这种关联仍然显著。所有关联在PRA三分位数中也得到证实,但在PAC三分位数中未得到证实。
在现实临床实践中,较高的RAR值表明肾素-血管紧张素-醛固酮系统受到有效抑制,夜间血压和脉压较低。它可能是接受ACE-I或ARB治疗的原发性高血压患者管理中的一个有用生物标志物。